AI

Cellular Origins, Fresenius Kabi partner for scalable CGT manufacturing

Cellular Origins and Fresenius Kabi have signed a development agreement to advance the automation of cell and gene therapy (CGT) manufacturing.

Medical technology

October 17, 2024

Cellular Origins and Fresenius Kabi have signed a development agreement to advance the automation of cell and gene therapy (CGT) manufacturing, according to a press release.

The collaboration aims to integrate Fresenius Kabi's cell therapy processing technologies with Cellular Origins' Constellation automation platform. This partnership is expected to enhance the scalability and efficiency of CGT production, addressing significant industry challenges.

Dr. Christian Hauer, president of MedTech at Fresenius Kabi, emphasized the importance of automation in overcoming research and manufacturing hurdles.

"For Fresenius Kabi, automation is crucial to addressing some of the biggest research and manufacture challenges in our industry. This is a major reason for our collaboration with Cellular Origins," Hauer said.

The initial phase of the project will concentrate on integrating the Cue Cell Processing System, designed for automated small volume processing, into the Constellation platform. This integration aims to create a fully automated, 24/7 CGT manufacturing system that maximizes space utilization and minimizes the need for personnel.

Dr. Edwin Stone, CEO at Cellular Origins, highlighted the significance of strong collaborations in the industry.

"Forming strong collaborations is essential to ensuring the industry can implement the transformative power of automation whilst using the tools that are best for the biology and, therefore, for patients," Stone said in the release.

The partnership aims to revolutionize CGT manufacturing by improving production efficiencies and reducing inconsistencies caused by human error.